ClinicalTrials.gg
RecruitingNCT07336277Updated Jul 30, 2026

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

A Phase 3 interventional study of Standard Postoperative Care and Zolpidem in Orthopedic Trauma and Sleep Quality, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Emory University · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Zolpidem · Sleep Initiation and Maintenance Disorders.

Planned enrollment
33rd of 40
30 · median 108
Started
2026
with 1 other
Phase 3
5 of 40
1 open now
Registered
38th of 40
by date

Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 3, and was the 38th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About zolpidem

Zolpidem: first FDA approval 1992 (AMBIEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The goal of this study is to determine whether a multimodal sleep pathway can enhance sleep quality in hospitalized patients with orthopedic trauma. It will also evaluate the effect of this pathway on opioid use and pain perception during recovery.

The main study questions are:

  • Does the multimodal sleep pathway improve sleep quality and duration?
  • Does the pathway reduce the amount of opioids patients use during hospitalization?
  • Does improved sleep reduce pain interference with daily activities?

Researchers will compare the multimodal sleep pathway to standard postoperative care to see if the pathway helps patients sleep better and rely less on opioids.

Participants will:

  • Receive either the multimodal sleep pathway (zolpidem, melatonin, and sleep hygiene education) or standard care
  • Wear a wrist-worn actigraphy device to track sleep during their hospital stay
  • Complete daily questionnaires about sleep quality and pain
Read the detailed description

Post-surgical orthopedic trauma patients frequently experience significant sleep disturbances, including reduced sleep quality, increased nighttime awakenings, and shortened sleep duration. Sleep and pain have a bidirectional relationship in which poor sleep increases pain sensitivity, and higher pain levels further disrupt sleep. Experimental sleep-restriction studies have shown that pain perception increases after only two nights of partial sleep deprivation and continues to worsen with each additional night. Despite these established interactions, objective sleep metrics have not been well characterized in the orthopedic trauma inpatient population, where postoperative pain, environmental disruptions, and medication use may all contribute to sleep disturbance.

Sleep patterns are also influenced by psychoactive substances, including opioids. Substance use and sleep-wake regulation share overlapping neurobiological pathways, and disruptions in circadian rhythms can occur during substance use, withdrawal, or detoxification. Although the mechanisms by which opioids alter sleep architecture are not fully understood, prior studies have shown that opioid exposure reduces restorative sleep stages, including deep sleep and rapid eye movement (REM) sleep, while increasing lighter stage-2 sleep. These changes may contribute to fragmented sleep and impaired recovery in postoperative patients who rely on opioids for pain management.

Non-opioid strategies have shown promise in improving sleep quality in hospitalized and postoperative patient populations. Behavioral approaches such as relaxation techniques, stimulus control, and structured sleep hygiene have been associated with improvements in sleep duration and continuity. Pharmacologic alternatives, including zolpidem and melatonin, have demonstrated benefit in orthopedic and general adult populations by supporting sleep initiation, circadian regulation, and overall sleep quality.

This study builds on these findings through two complementary aims. Aim 1 analyzes previously collected actigraphy and survey data from a randomized controlled trial of adults with isolated orthopedic injuries (NCT04154384). In that study, participants wore wrist-worn actigraphy devices during hospitalization and completed validated sleep and pain assessments at baseline and postoperative follow-up visits. Preliminary analyses indicate that patients experience short, fragmented sleep and that higher opioid utilization may be associated with decreased sleep quantity and quality. Further analysis is needed to characterize these relationships using objective sleep metrics and detailed opioid timing and dosing data.

Aim 2 evaluates a multimodal sleep pathway designed to improve sleep quality and reduce opioid use during inpatient recovery. In a prospective randomized controlled trial, participants are assigned to receive either standard postoperative care or a sleep pathway that includes low-dose zolpidem, melatonin, and structured sleep hygiene education. The intervention begins on the first postoperative night and continues daily until discharge. Sleep outcomes are assessed using daily subjective questionnaires and continuous wrist actigraphy. Opioid consumption is recorded and converted to morphine milligram equivalents to allow standardized comparison. Pain perception is measured using validated patient-reported tools. Feasibility outcomes include recruitment, adherence to the intervention, actigraphy wear compliance, and retention through discharge. Safety monitoring includes assessment for medication-related side effects and actigraphy-related discomfort.

Together, these aims will provide foundational data on the relationship between opioid use and sleep quality in orthopedic trauma patients and will evaluate whether a structured multimodal sleep intervention can improve sleep and reduce reliance on opioids during hospitalization. Findings will inform the design of future larger-scale trials aimed at optimizing sleep and recovery in this population.

03

Conditions studied

  • Orthopedic Trauma
  • Sleep Quality

Keywords

  • Multimodal Sleep Pathway
  • Sleep Quality
  • Opioid consumption
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with an isolated lower extremity orthopedic injury requiring surgical intervention.
  • Expected hospital stay of at least 3 days.
  • No known pre-existing sleep disorders.
  • No current use of sleep aids, such as zolpidem or melatonin, before hospitalization

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of chronic opioid use prior to hospitalization.
  • Pre-existing diagnosed sleep disorders (e.g., obstructive sleep apnea, insomnia).
  • to zolpidem or melatonin use (e.g., allergies, interactions with other medications).
  • Cognitive impairment or inability to comply with study procedures.
  • Severe traumatic brain injury or other neurological conditions that may affect sleep or pain perception.
  • Participants receiving mechanical ventilation or sedatives that significantly affect sleep architecture.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Multimodal Sleep Pathway

    Participants receive a multimodal sleep pathway consisting of pharmacologic sleep aids and non-pharmacologic sleep hygiene education beginning on the first postoperative night and continuing daily until hospital discharge.

    Drug: Zolpidem · Dietary Supplement: Melatonin · Behavioral: Sleep Hygiene Education · Device: Actigraph GT3X-BT Actigraph

  • Other
    Standard Care

    Participants receive routine postoperative care without sleep-specific pharmacologic or behavioral interventions. Standard pain management is provided per the clinical team's discretion.

    Other: Standard Postoperative Care · Device: Actigraph GT3X-BT Actigraph

Interventions

  • OtherStandard Postoperative Care

    Includes routine pain management and nursing care

  • * Dose: 5 mg * Administration: Taken nightly at bedtime * Purpose: Supports sleep initiation as part of the multimodal sleep pathway * Additional Notes: FDA-approved sedative-hypnotic used short-term for insomnia

  • Dietary supplementMelatonin

    * Dose: 3 mg * Administration: Taken 30 minutes before bedtime * Purpose: Supports circadian regulation and sleep continuity

  • BehavioralSleep Hygiene Education

    * Components: Guidance on consistent sleep schedules, minimizing nighttime disruptions, reducing screen exposure before bed, and optimizing environmental factors (light, noise, temperature) * Delivery: Provided by research staff daily during hospitalization

  • DeviceActigraph GT3X-BT Actigraph

    The ActiGraph GT3X-BT (ActiGraph, LLC; Pensacola, FL) is a lightweight, wrist-worn accelerometer used to objectively measure sleep-wake patterns in hospitalized patients. The device continuously records movement data that are processed using validated algorithms to estimate total sleep time, sleep efficiency, and number of awakenings.

06

What researchers measure

Primary outcomes

  1. Total Sleep Time

    Total minutes of sleep obtained each night, measured continuously using a wrist-worn actigraphy device (Actigraph GT3X-BT). Between-group differences in total sleep time will be evaluated using independent t-tests or Mann-Whitney U tests, depending on distribution. Longitudinal changes will be analyzed using linear mixed-effects models with random intercepts to account for repeated measures. Covariates may include age, injury characteristics, and baseline pain levels.

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  2. Sleep Efficiency

    Percentage of time spent asleep while in bed, calculated from actigraphy data collected continuously during hospitalization. Group comparisons will be conducted using independent t-tests or nonparametric equivalents. Mixed-effects modeling will assess within-subject changes over time and the effect of group assignment.

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  3. Number of Awakenings

    Total number of nighttime awakenings detected by actigraphy, reflecting sleep fragmentation. Awakening counts will be compared between groups using Poisson or negative binomial regression models, depending on dispersion. Mixed-effects count models will evaluate changes over time.

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  4. Subjective Sleep Quality: PROMIS scale

    The PROMIS Sleep Disturbance Short Form assesses self-reported perceptions of sleep quality, sleep depth, and restoration over the past 7 days. Items are rated on 5-point Likert scales and summed to produce a raw score, which is converted to a standardized PROMIS T-score. Higher T-scores indicate greater sleep disturbance (worse sleep), and lower T-scores indicate less sleep disturbance (better sleep).

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  5. Subjective Sleep Quality: Leeds Sleep Evaluation Questionnaire (LSEQ)

    The LSEQ is a 10-item patient-reported questionnaire that assesses subjective changes in sleep and early-morning functioning using 100-mm visual analogue scales. Items evaluate four domains: Getting to Sleep (GTS), Quality of Sleep (QOS), Awakening From Sleep (AFS), and Behavior Following Waking (BFW). Each item is scored from 0-100 mm, with higher scores indicating greater improvement relative to usual sleep and lower scores indicating worsening.

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  6. Daily Opioid Utilization

    Total opioid consumption recorded from the medical record and converted to morphine milligram equivalents (MMEs) to allow standardized comparison across medication types and dosing regimens.

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

Secondary outcomes

  1. Pain Interference

    Patient-reported pain interference with daily activities measured using a validated pain interference scale. Higher scores indicate greater interference

    Time frame: Daily during inpatient hospitalization (approximately 3-7 days)

  2. Recruitment Feasibility

    Assesses the proportion of eligible orthopedic trauma patients who enroll in the study during the inpatient recruitment window. Recruitment feasibility reflects the practicality of identifying, approaching, and enrolling participants in an acute trauma setting. Recruitment rate will be calculated as the number of enrolled participants divided by the number of eligible patients approached. Results will be summarized using proportions and 95% confidence intervals.

    Time frame: Throughout the study (upto 7 days of hospital stay)

  3. Adherence to Pharmacologic Components

    Assesses adherence to the medication components of the multimodal sleep pathway, defined as the proportion of nights during which participants receive the prescribed low-dose zolpidem and melatonin as ordered. Adherence will be summarized as the percentage of scheduled doses administered. Means, standard deviations, and proportions will be reported.

    Time frame: Throughout the study (upto 7 days of hospital stay)

  4. Adherence to Non-Pharmacologic Components

    Assesses adherence to daily sleep hygiene education, including completion of brief educational sessions delivered by research staff. Adherence reflects the feasibility of implementing behavioral components in a busy inpatient trauma environment. Adherence will be summarized descriptively as the proportion of days on which sleep hygiene education was completed. Percentages and confidence intervals will be reported.

    Time frame: Throughout the study (upto 7 days of hospital stay)

  5. Actigraphy Wear-Time Compliance

    Assesses the proportion of hospitalization hours during which the ActiGraph GT3X-BT device records valid data. This measure assesses the feasibility and tolerability of continuous wrist-worn actigraphy in patients with orthopedic trauma. Wear-time compliance will be calculated as the percentage of total hospitalization hours with valid actigraphy data. Descriptive statistics (means, SDs, ranges) will be reported.

    Time frame: Throughout the study (upto 7 days of hospital stay)

  6. Retention Through Discharge

    Assesses the proportion of enrolled participants who complete all study procedures through hospital discharge without withdrawal or protocol discontinuation. Retention will be summarized as the percentage of participants completing the study through discharge. Proportions and 95% confidence intervals will be reported.

    Time frame: Throughout the study (upto 7 days of hospital stay)

  7. Adverse Events Related to Study Interventions

    Incidence of medication-related side effects (e.g., dizziness, drowsiness, complex sleep behaviors), melatonin intolerance, or actigraphy-related discomfort. Adverse events will be summarized using frequencies and proportions. Between-group comparisons may use Fisher's exact test.

    Time frame: Throughout the study (upto 7 days of hospital stay)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study team will share all non-protected data upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Upon completion of the study.

Access criteria: Reaching out to the PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 13 months after the start.

Of 42 phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 13, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07336277
Lead sponsor
Emory University
Collaborators
AO North America
Responsible party
Mara Schenker (Professor, Emory University) — Principal investigator
First posted
Jan 13, 2026
Start date
Jun 2, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 30, 2026

Study contacts

Mara Schenker, MD
Contact
mara.schenker@emory.edu
404-778-1550
Tyler Edmond, MD
Contact
tjedmon@emory.edu
Mara Schenker, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zolpidem · Melatonin

Start the discussion